key: cord-0737465-f3cxvw2x authors: Luger, Anna K.; Sonnweber, Thomas; Gruber, Leonhard; Schwabl, Christoph; Cima, Katharina; Tymoszuk, Piotr; Gerstner, Anna K.; Pizzini, Alex; Sahanic, Sabina; Boehm, Anna; Coen, Maximilian; Strolz, Carola J.; Wöll, Ewald; Weiss, Günter; Kirchmair, Rudolf; Feuchtner, Gudrun M.; Prosch, Helmut; Tancevski, Ivan; Löffler-Ragg, Judith; Widmann, Gerlig title: Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD Study date: 2022-03-29 journal: Radiology DOI: 10.1148/radiol.211670 sha: 4888403ea10a98b95c9633832b2d3e0739d47e10 doc_id: 737465 cord_uid: f3cxvw2x BACKGROUND: The long-term pulmonary sequelae of coronavirus disease 2019 (COVID-19) is not well known. PURPOSE: To characterize patterns and rates of improvement of chest CT abnormalities one year after COVID-19 pneumonia. MATERIALS AND METHODS: This was a secondary analysis of a prospective, multicenter observational cohort study conducted from April 29 to August 12, 2020 to assess pulmonary abnormalities on chest CT at approximately 2, 3, 6 months, and 1 year after onset of COVID-19 symptoms. Pulmonary findings were graded for each lung lobe using a qualitative CT severity score (CTSS), range 0 (normal) to 25 (all lobes involved). The association of demographic and clinical factors with CT abnormalities after 1 year was assessed with logistic regression. The rate of change of the CTSS at follow-up CT was investigated by Friedmann test. RESULTS: Out of 142 enrolled participants, 91 participants had a 1-year follow-up CT and were included in the analysis [mean age, 59 years ± 13 [standard deviation]; 35 women (38%)]. In 49/91 (54%) participants, CT abnormalities were observed: 31/91 (34%) participants showed subtle subpleural reticulation, ground-glass opacities or both and 18/91 (20%) participants revealed extensive ground-glass opacities, reticulations, bronchial dilation and/or microcystic changes. In multivariable analysis, age > 60 years (OR 5.8 [95% CI: 1.7 - 24]; p = .009) critical COVID-19 severity (OR 29 [95% CI: 4.8 - 280]; p < .001) and male gender (OR 8.9 [95% CI: 2.6 - 36]; p < .001) were associated with persistent CT abnormalities at 1 year. Reduction of CTSS was observed in participants in subsequent follow-up CTs (p < .001) and during the study period 49% (69/142) of participants had complete resolution of CT abnormalities. 31/49 (63%) participants with CT abnormalities did not show further improvement after 6 months. CONCLUSION: Long-term CT abnormalities were common 1 year after COVID-19 pneumonia. The study is registered at ClinicalTrials.gov number (registration number NCT04416100). See also the editorial by Leung. The coronavirus disease 2019 pandemic, caused by the novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has affected all countries worldwide and considerably increased the demand for acute and post-acute healthcare. As of January 11, 2022 , over 300 million COVID-19 cases and 5.5 million COVID-19 related deaths are reported by the WHO (WHO dashboard, accessed January 11, 2022). COVID-19 primarily presents with pulmonary symptoms (1) . SARS-CoV-2 mainly spreads via the respiratory tract (2) and can cause respiratory symptoms leading to respiratory insufficiency. Most patients admitted to the hospital display signs of poor oxygenation as a consequence of pneumonia, which can progress to acute respiratory distress syndrome (ARDS) (3) . Radiological appearance of acute COVID-19 pneumonia is dominated by ground-glass opacities (GGO) and focal consolidations (4) . Histological changes in early stages of COVID-19 pneumonia included spots of patchy acute lung injury with alveolar type II cell hyperplasia and enlarged interalveolar capillaries, without evidence of hyaline membranes (5) . CT follow-up four to ten weeks post COVID-19 pneumonia demonstrate pulmonary parenchymal abnormalities in 45-63% of patients (6, 7) . However, the long-term pulmonary outcome is not well known (8) . A large impact on health care systems due to long-term sequelae of COVID-19 is to be expected due to the potential pulmonary long-term sequelae (9) . In the Austrian state Tyrol, an observational study on the development of interstitial lung disease in patients with SARS-CoV-2 infection (CovILD)was designed to prospectively evaluate pulmonary recovery after the first COVID-19 wave. In this report, our study aim was to characterize patterns and rates of improvement of chest CT abnormalities one year after COVID-19 pneumonia. The CovILD study is a prospective, multicenter, observational cohort study (ClinicalTrials.gov number, NCT04416100) conducted from April 29, to August 12, 2020 to assess the extent of CT abnormalities on chest CT. Follow-up visits were scheduled at 2, 3, and 6 months and 1 year after initial COVID-19 symptoms, however deviations up to twenty days were accepted due to I n p r e s s clinical or logistic reasons. Low-dose chest CT scans (<1.5 mSv effective dose) were performed at every follow-up visit. Participants aged 18 years or older who suffered from mild to severe COVID-19 were screened consecutively at the study centers (Innsbruck Medical University, REHA Center Münster, Austria and St. Vinzenz hospital, Zams, Austria). Exclusion criteria were the rejection of study participation and poor CT image quality. Disease severity was graded clinically: mild (outpatient care); moderate (hospitalization without respiratory support); severe (hospitalization in need of oxygen supply); critical (patients treated at the intensive care unit (ICU) in need of invasive or non-invasive ventilation) (7) . The study was conducted in accordance with the Declaration of Helsinki and European Data Policy. All participants gave informed written consent. The study was granted approval by the institutional review board at the Innsbruck Medical University (approval number: 1103/2020). CT scans were acquired on a 128-slice multidetector CT scanner (SOMATOM Definition Flash, Siemens Healthineers) without contrast agent or electrocardiographic (ECG) gating. Exams were performed at full inspiration. Scans were obtained with 0.6 mm collimation and spiral pitch factor of 1.1 in craniocaudal direction and in a low-dose setting (100 kVp tube potential and 50mAs). Axial reconstructions were performed with a section thickness of 1 mm and an interval of 0.8 mm, sagittal and coronal reconstructions with 3 mm section thickness using a hard kernel (I30f) as well as a soft kernel (I50f). All CT images were reviewed independently by three radiologists (G.W., A.K.L and C.S. with 16, 8 , and 3 years of experience in thoracic radiology, respectively), and discrepancies were resolved by consensus. Readers were blinded to the participants' initial and subsequent clinical presentation but were allowed to review the CTs obtained at the previous follow-up visits. In a subgroup of participants (n= 48), a chest CT was available upon initial hospital admission. CT scans, which had been assessed during the acute phase of the disease were additionally analyzed for the presence of radiological findings typical for acute respiratory distress syndrome (ARDS) or organizing pneumonia (OP) patterns. ARDS was defined by radiological diffuse alveolar damage patterns, i.e. geographic or diffuse ground-glass opacities or consolidations involving large parts of the lung. Lower lobe predominance, interlobular septal I n p r e s s thickening, and crazy paving were also attributed to ARDS (10) . Diagnosis of OP was based on the presence of ground-glass opacities (GGO) and/or airspace consolidation in subpleural, basal, or peribronchial distribution and further characterized by the typical arcade-like sign or atoll sign (11) . Additionally, the recently described vessel tree-in-bud sign in COVID-19 pneumonia was also considered (12) . Pulmonary findings were graded for each lobe using a previously published CT severity score (CTSS): 0-none, 1-minimal (subtle GGO, very few findings), 2-low (several GGO and/or subtle reticulation), 3-moderate (multiple GGO, reticulation and/or small consolidation), 4-marked (extensive GGO, consolidation and/or reticulation with distortion), and 5-massive (massive findings and/or parenchymal destructions). The maximum score was 25 (i.e., maximum score of 5 per lobe (7)). We only considered structural alterations as CT abnormalities if confirmed to be in the same location as the initial CT findings of the affected lung areas. In addition, the Syngo.via CT Pneumonia Analysis (Version 2, Siemens Healthineers, Erlangen, Germany) research prototype for the detection and quantification of abnormalities in chest CT consistent with pneumonia was used to evaluate the percentage of opacity (corresponding to GGO) and high opacity (corresponding to consolidation) (7). Data were analyzed with R version 4.0.5 with tidyverse environment and ggplot2 package for result visualization (pipeline available at GitHub: https://github.com/PiotrTymoszuk/radio_CovILD). Normality of variables and model residuals was assessed by qq plots and Shapiro-Wilk test, homoscedasticity was assessed by Levene's test. Non-normally distributed parameters age (stratification cutoff 60 years), body mass index (BMI cutoffs 25 and 30 kg/m²) and pack-years (PKY cutoffs 0, 1, 10, 20) were categorized. Differences in frequencies of clinical and CT features between the follow-ups or COVID-19 severity strata were investigated by χ 2 test. Risk factors (explanatory variables: sex, age, BMI class, smoking history, pack-years, acute COVID-19 severity) associated with 1-year follow-up CT abnormalities were identified by univariable logistic regression. Factors associated with the severity of chest CT abnormality (absent, 1 -5, 6 -10, 11 -25 CTSS) were identified by univariable ordinal logistic regression. . Multi-parameter models were constructed by Akaike I n p r e s s Information Criterion (AIC) -directed backwards term elimination from the full multi-parameter model (initial explanatory variables: sex, age, BMI class, smoking history, pack-years, acute COVID-19 severity) and 20-fold cross-validated. Change of CTSS value over time (n = 58 participants with complete longitudinal CT record) was investigated by Friedman test, the global effect size was estimated by Kendall's W. Differences in CTSS between the consecutive visits were compared with paired Wilcoxon post-hoc test and r effect size statistic. Correlation of CTSS and percentage opacity was investigated with Spearman test. Effects with p < 0.05 were considered significant. Of 190 participants that were screened, 142 were enrolled, and 91 were included in this secondary analysis (Fig 1) . The mean age was 59 years ± 13 (standard deviation) and 35 of the participants were women (38%). 19/91 (25%) participants received outpatient treatment (mild disease severity), 23/91 (25%) were hospitalized without respiratory support (moderate), 23/91 (25%) were hospitalized in need of oxygen supply (severe) and 26/91 (29%) participants were treated at ICU (critical) ( Table 1) . 49 of 91 (54%) participants, who attended the 1-year follow-up visit displayed pulmonary CT abnormalities. The predominant pulmonary abnormalities were GGO in 44% (40/91) and subpleural reticulations in 44% (40/91) of participants. The combination of both patterns was found in 34% (31/91) of participants. In a minor percentage, subpleural curvilinear lines (4/91, 4.4%) and bronchial dilation (9/91, 10%) were observed. Notably, none of the participants presented with honeycombing. Table 2 lists all pulmonary changes in detail for each follow-up. Of the 49 participants with CT abnormalities at the 1-year CT, two (4%) had received outpatient treatment only, while 25 (51%) were treated on a general hospital word and 22 (45%) had received intensive care unit treatment (ICU). Of those who had been in an ICU, 21/22 (95%) had been intubated. After 1 year, 34% (31/91) of participants showed minimal CT abnormalities, reflected by a CTSS of ≤ 1 per lobe, with a total score ≤ 5. In these participants, chest CT revealed subtle I n p r e s s reticulations and/or GGO. In 20% (18/91) of participants, CTSS was > 5 and CT depicted marked reticulation, extensive GGO, parenchymal distortion, bronchial dilatation and/or microcystic changes. A pictorial illustration of CT severity score is shown in figure 2 . The CT abnormalities of pure GGO and/or reticulations found in 49 participants at the first follow-up resolved entirely in 39% (19/49) at 1 year. By contrast, all 19 participants (100%, 19/19) with either consolidation or bronchial dilation or OP pattern at 2 months also showed CT abnormalities after one year. In univariable analysis (Fig 3A) and age ≤ 60) (Fig 3B) . CT results at one year assessed by the CTSS score generally paralleled the above findings ( Fig E1 [online] ). In the multivariable analysis, participants with critical severity of COVID-19, male gender and age greater than 60 years had a higher risk of developing more severe CT abnormalities than the reference group (reference: female, non-critical COVID-19 and age ≤ 60). Most participants showed gradual improvement of pulmonary injury in subsequent follow-up CT scans (Fig 4) . The median CT severity scores were 8.5, 3, 2 and 1 at follow-up CT at 2, 3, 6 months and 1 year, respectively (Fig 5) . The rate of recovery of chest CT abnormalities in the whole cohort was slower between 1-year versus 6-month follow-up (p < .001; r = 0.84) as In 44% (40/91) the CT abnormalities resolved completely. 63% (31/49) of participants with CT abnormalities had no amelioration of these CT abnormalities after 6 months, which was confirmed by a side-by-side comparison of the CT scans. In general, the software-based automated opacity quantification displayed high concordance with radiologist-assessed CTSS (r ≥ 0.81) (Fig E2 [online] ). However, especially at the later follow-ups, up to 14% of CT abnormalities were not recognized by the software. Chest CT during acute COVID-19 was available for 48 participants. Of these, 3 (6.3%) had mild, Despite the shorter follow-up period in our cohort, the observed temporal resolution is consistent with these previous findings, suggesting persisting but stable CT abnormalities after COVID-19. However, due to the far smaller case numbers of SARS-CoV-1 and the broad spectrum of SARS-CoV-2 infections, a direct comparison should be considered with caution at this point of the still ongoing pandemic. To evaluate the extent of pulmonary alterations, recent COVID-19 studies used a semiquantitative CT score, consisting of five groups according to the percentage of affected lung parenchyma (<5 %, 5-25%, 26-50%, 51-75%, >75%) (16) . However, from our experience, it was very difficult to estimate the extent of subtle GGO and almost impossible to estimate the percentage of irregular lines, subpleural lines, or interlobular septal thickening which were the most common signs of CT abnormalities in our cohort. Furthermore, the software-based I n p r e s s quantitative evaluation lacked sensitivity for those subtle radiologic changes. The clinical effect of these mild findings might be gained by their comparison to the pattern of interstitial lung abnormalities (ILAs), which have already been shown to potentially progress to pulmonary fibrosis (17) . We analyzed if the development of CT abnormalities could be associated with imaging markers or disease severity. Notably, CT imaging findings, which were assessed at the acute or the early post-acute follow-up (2 months after symptom onset), allowed reliable prediction of the occurrence of CT abnormalities. Similarly, the study by Han et al. found an association between ARDS and the presence of fibrotic-like changes after six months (18) . This observation might be of clinical significance as it revealed CT patterns at an early point in the course of disease that might provide a profound basic principle for future therapeutic intervention studies, e.g. the evaluation of anti-inflammatory or anti-fibrotic medication regimes to prevent marked residues. Only half of the participants with CT abnormalities at the long-term follow-up were treated in an ICU during acute disease. The remaining 50% were treated in a general ward or even in an outpatient care setting. This demonstrates that long-term CT abnormalities are not an exclusive feature merely found after critical COVID-19, which correlates with the results by Wu et al. (13) . Persistent pulmonary abnormalities after ARDS have so far been explained by the pulmonary disease itself and by the harmful effects of mechanical ventilation (19) . However, the hypothesis of specific COVID-19 triggered interstitial lung disease has recently been established (20) . Our findings provide additional evidence that independent of progressing to ARDS or barotrauma the natural course of COVID-19 pneumonia itself contributes to the structural lung damage. Our study had several limitations. We did not correlate CT abnormalities with lung function testing, which will be required to understand the clinical outcome of these structural alterations. Approximately one third of patients were lost to follow-up at 12 months with unknown bias on study results. Study participants were recruited during the first wave of the pandemic in Europe (March to June 2020), and treatment algorithms have changed over time. For instance, corticosteroids are now recommended for severe COVID-19 to ameliorate acute I n p r e s s inflammatory responses. None of the participants in our study were treated with corticosteroids in the early phase of infection. Finally, interstitial lung abnormalities (ILAs) may be present in approximately 10% of the population (21) . To distinguish pre-existing ILAs from CT abnormalities after COVID-19, we only considered structural abnormalities as postinfectious CT abnormalities if confined to previous COVID-19 pneumonia affected lung areas. In conclusion, our results emphasize early and longitudinal monitoring of COVID-19 participants. Unfortunately, there is still an urgent need for further studies focusing on histological and clinical correlations within the first three months after COVID-19 to identify participants at risk for developing CT abnormalities and who would benefit from early tailored therapeutic concepts. OP pattern 6 (7.9) 6 (7.1) 2 (2.9) 0 (0) .04 I n p r e s s Clinical features of patients infected with 2019 novel coronavirus in Wuhan Characteristics of SARS-CoV-2 and COVID-19 Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey Covid-19 Interstitial Pneumonia: Histological and Immunohistochemical Features on Cryobiopsies Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities Lung CT: Part 2, The interstitial pneumonias--clinical, histologic, and CT manifestations Fleischner Society: glossary of terms for thoracic imaging Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19 Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19) Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia Changes in lung parenchyma after acute respiratory distress syndrome (ARDS): assessment with high-resolution computed tomography Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties Interstitial Lung Abnormality: Recognition and Perspectives This study was supported by Boehringer Ingelheim RCV GmbH & Co KG (BI). BI had no role in the design, analysis or interpretation of the results in this study. BI was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BIPI substances, as well as intellectual property considerations. Funding information for this article has been deposited with the Crossref Funder Registry.